Categories: News

StageZero Announces Third Quarter Analyst and Investor Call

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

TORONTO, ON / ACCESSWIRE / December 7, 2020 / StageZero Life Sciences (“StageZero” or the “Company”) (TSX:SZLS) today announced StageZero’s Chairman and CEO, James R Howard-Tripp, will host a conference call and online presentation at 8:30 am ET on Tuesday December 8th to review the operational results and discuss business developments for the period and to date.

Analyst and Investor Call

Event Date: Tuesday December 8, 2020
Time: 8:30 – 9.15 AM EST
Webcast Link: https://www.webcaster4.com/Webcast/Page/2082/39114

Participant Numbers: Toll Free: 877-407-8031
International: 201-689-8031

Replay Number: Toll Free: 877-481-4010
International: 919-882-2331

Replay Passcode: 39114

About StageZero Life Sciences, Ltd.

StageZero Life Sciences is dedicated to the early detection of multiple disease states through whole blood. The Company operates a CAP accredited and CLIA certified high complexity reference laboratory based in Richmond, Virginia. A specialist in PCR testing for the early identification of Cancer through blood, the Company is uniquely positioned to provide both COVID PCR testing (saliva and swab) and blood test analysis (Antibody testing). Our full service, telehealth platform includes access to physicians and mobile phlebotomists and nurses who can prescribe and draw samples for individuals and groups. As we provide COVID-19 testing during this Pandemic, we continue making progress with our mission to eradicate late stage cancers through early detection. Our next generation test, Aristotle®, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. www.stagezerolifesciences.com

Company Contacts:

James R. Howard-Tripp
Chairman & CEO
jht@stagezerols.com
Tel: 1-855-420-7140 Ext. 1

Rebecca Greco
Investor Relations
rgreco@stagezerols.com
Tel: 1-855-420-7140 Ext. 1838

SOURCE: StageZero Life Sciences Ltd

View source version on accesswire.com:
https://www.accesswire.com/619761/StageZero-Announces-Third-Quarter-Analyst-and-Investor-Call

Staff

Recent Posts

CONMED Corporation to Announce Second Quarter 2025 Financial Results on July 30, 2025

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for…

7 hours ago

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025

MARLBOROUGH, Mass.--(BUSINESS WIRE)--$HOLX #earnings--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release…

7 hours ago

inTouch Addresses $6.7 Billion Senior Loneliness Crisis with Launch of AI Conversational Companion for North America

Complements Family Interactions & Supports Sandwich Generation of Caregivers with Daily Phone Calls to Seniors…

7 hours ago

AI in Healthcare: MENA Region on the Verge of a Major Breakthrough

"Comprehensive Analysis of MENA's AI Healthcare Market: Emerging Opportunities and Challenges, with a Projected CAGR…

7 hours ago

Global Excel Acquires First Assistance to Strengthen Assistance Services and Expand in the Asia-Pacific Market

SHERBROOKE QC, July 2, 2025 /PRNewswire/ - Global Excel Management Inc. (Global Excel) is pleased…

7 hours ago

Single Pass Inc. Launches Global Post-Market Evaluation of the Biopsy Tract Closure Device

The evaluation will include 1,000 unique procedures across 20 centers worldwide to capture real-world evidence…

13 hours ago